Trials / Completed
CompletedNCT00369148
Combination of Glinides With Premixed Insulin
Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Keio University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Combination therapy of glinides with premixed insulin provides better glycemic control than premixed insulin alone.
Detailed description
Type 2 diabetic patients undergoing twice daily injections of premixed insulin are administered glinides (10mg of mitiglinide or 90 mg of nateglinide) at lunchtime without changing their insulin regimen. Twelve weeks after administration of the glinides, they are discontinued. HbA1c levels at the start of glinide administration, 12 weeks after administration, and 12 weeks after discontinuation are measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nateglinide(drug) mitiglinide(drug) |
Timeline
- Start date
- 2004-07-01
- Completion
- 2006-03-01
- First posted
- 2006-08-29
- Last updated
- 2009-08-26
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00369148. Inclusion in this directory is not an endorsement.